Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Pimavanserin 34 mg vs NUPLAZID in Healthy Volunteers
NCT06450184Phase 1Completed
- Sponsor
- Humanis
- Start
- Jan 2024
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pimavanserin in Parkinson's disease (PD) (2 arms), sponsored by Humanis. Primary endpoints: Maximum concentration obtained at 23 hours and AUC from time 0 to last collection time 72 at 23 hours. Started Jan 2024; status: completed.
02
Drugs
pimavanserin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06450184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06450184.